Literature DB >> 2599960

Limb-sparing treatment for osteosarcoma in dogs.

S M LaRue1, S J Withrow, B E Powers, R H Wrigley, E L Gillette, P D Schwarz, R C Straw, S L Richter.   

Abstract

Twenty dogs with spontaneously developing osteosarcoma of the extremities were treated with 1 of 3 multimodality limb-sparing procedures. Excision of the tumor was preceded by intra-arterial (IA) administration of cisplatin (cis-diamminedichloroplatinum) alone directed to the affected extremity, irradiation plus IA administration of cisplatin, or irradiation plus IV administration of cisplatin. All dogs were free of apparent metastatic disease at the time of initial treatment. After diagnosis, dogs administered cisplatin IA had selective angiography performed on arteries supplying the tumor, and 70 mg of cisplatin/m2 of body surface was administered over 2 hours. This protocol was repeated 3 weeks later. Dogs that were irradiated received 25 or 40 Gy in 10 fractions over a 22-day period. The first and last radiation doses were immediately preceded by IA administration of cisplatin. Dogs given IV treatment received 10 mg of cisplatin/m2 2 hours before each radiation fraction was administered. Three weeks after the last treatment, tumors were excised and the limb underwent orthopedic reconstruction, generally using cortical allografting and bone plating. Limb function, allograft healing, local tumor control, and metastatic dissemination were monitored. Limb function was good to excellent in 69% (11/16) of dogs evaluated. Forelimb-sparing procedures were generally associated with better function than were limb-sparing procedures performed on hind limbs. Local tumor control was obtained in 79% (11/14) of dogs thoroughly evaluated, with local recurrences in 3 dogs at 3, 4, and 7 months after treatment. Fifteen dogs developed metastatic disease at a median time of 8 months from the time of diagnosis. Mean and median survival times for all dogs, regardless of cause of death, were 11.7 and 8 months, respectively. Tumor necrosis greater than 80% was statistically associated with lack of recurrence. Of 16 dogs, 5 (31%) developed infections at the surgical site. Multimodality limb-sparing treatment is believed to be a viable alternative for appropriately selected dogs with osteosarcoma. The optimal method of treatment prior to or after tumor excision has not yet been established.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2599960

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  13 in total

1.  Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression.

Authors:  Melissa Paoloni; Sean Davis; Susan Lana; Stephen Withrow; Luca Sangiorgi; Piero Picci; Stephen Hewitt; Timothy Triche; Paul Meltzer; Chand Khanna
Journal:  BMC Genomics       Date:  2009-12-23       Impact factor: 3.969

2.  Accuracy of computed tomography in determining lesion size in canine appendicular osteosarcoma.

Authors:  Ketaki S Karnik; Valerie F Samii; Steven E Weisbrode; Cheryl A London; Eric M Green
Journal:  Vet Radiol Ultrasound       Date:  2012-03-14       Impact factor: 1.363

Review 3.  Dog models of naturally occurring cancer.

Authors:  Jennie L Rowell; Donna O McCarthy; Carlos E Alvarez
Journal:  Trends Mol Med       Date:  2011-03-24       Impact factor: 11.951

Review 4.  Comparative oncology today.

Authors:  Melissa C Paoloni; Chand Khanna
Journal:  Vet Clin North Am Small Anim Pract       Date:  2007-11       Impact factor: 2.093

Review 5.  Canine sarcomas as a surrogate for the human disease.

Authors:  Daniel L Gustafson; Dawn L Duval; Daniel P Regan; Douglas H Thamm
Journal:  Pharmacol Ther       Date:  2018-03-09       Impact factor: 12.310

6.  Methimazole as a protectant against cisplatin-induced nephrotoxicity using the dog as a model.

Authors:  D M Vail; A A Elfarra; A J Cooley; D L Panciera; E G MacEwen; S A Soergel
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 7.  Companion animals: Translational scientist's new best friends.

Authors:  Amir Kol; Boaz Arzi; Kyriacos A Athanasiou; Diana L Farmer; Jan A Nolta; Robert B Rebhun; Xinbin Chen; Leigh G Griffiths; Frank J M Verstraete; Christopher J Murphy; Dori L Borjesson
Journal:  Sci Transl Med       Date:  2015-10-07       Impact factor: 17.956

Review 8.  Prognostic factors in canine appendicular osteosarcoma - a meta-analysis.

Authors:  Ilse Boerman; Gayathri T Selvarajah; Mirjam Nielen; Jolle Kirpensteijn
Journal:  BMC Vet Res       Date:  2012-05-15       Impact factor: 2.741

Review 9.  Animal models and therapeutic molecular targets of cancer: utility and limitations.

Authors:  Maria Cekanova; Kusum Rathore
Journal:  Drug Des Devel Ther       Date:  2014-10-14       Impact factor: 4.162

10.  A novel derivative of doxorubicin, AD198, inhibits canine transitional cell carcinoma and osteosarcoma cells in vitro.

Authors:  Kusum Rathore; Maria Cekanova
Journal:  Drug Des Devel Ther       Date:  2015-09-25       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.